Equities research analysts forecast that Agile Therapeutics, Inc. (NASDAQ:AGRX) will report earnings of ($0.25) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Agile Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.27). Agile Therapeutics posted earnings of ($0.27) per share during the same quarter last year, which would suggest a positive year over year growth rate of 7.4%. The firm is expected to announce its next quarterly earnings report on Monday, November 6th.

According to Zacks, analysts expect that Agile Therapeutics will report full-year earnings of ($1.03) per share for the current year, with EPS estimates ranging from ($1.06) to ($0.98). For the next financial year, analysts anticipate that the company will post earnings of ($0.78) per share, with EPS estimates ranging from ($1.28) to ($0.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. During the same period in the previous year, the business posted ($0.29) earnings per share.

A number of research firms have recently weighed in on AGRX. Royal Bank Of Canada set a $8.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Sunday, July 16th. Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a research report on Sunday, July 30th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $13.00 price target (down previously from $15.00) on shares of Agile Therapeutics in a research report on Thursday. HC Wainwright started coverage on shares of Agile Therapeutics in a research report on Wednesday, July 19th. They set a “buy” rating and a $10.00 price target for the company. Finally, ValuEngine raised shares of Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $8.75.

Institutional investors have recently modified their holdings of the company. Royal Bank of Canada increased its stake in Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 27,907 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Agile Therapeutics during the second quarter valued at about $122,000. Susquehanna International Group LLP acquired a new stake in Agile Therapeutics during the second quarter valued at about $205,000. LMR Partners LLP acquired a new stake in Agile Therapeutics during the second quarter valued at about $211,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Agile Therapeutics during the second quarter valued at about $309,000. 67.59% of the stock is owned by hedge funds and other institutional investors.

Shares of Agile Therapeutics (AGRX) traded down 2.10% on Monday, hitting $3.26. The company’s stock had a trading volume of 147,784 shares. The firm’s market cap is $93.91 million. The stock has a 50-day moving average price of $3.95 and a 200 day moving average price of $3.33. Agile Therapeutics has a one year low of $1.82 and a one year high of $7.95.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/zacks-brokerages-anticipate-agile-therapeutics-inc-agrx-to-announce-0-25-eps/1528340.html.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.